Zafgen
29 Newbury Street
Boston
Massachusetts
02116
United States
Tel: 617-236-0535
Fax: 617-249-0490
Website: http://www.zafgen.com/
Email: info@zafgen.com
126 articles about Zafgen
-
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
5/29/2020
- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused institutional investors - New Board Chair, Chief Medical Officer and Chief Financial Officer appointed BALA CYNWYD, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Chondrial Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today ann
-
Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results
3/5/2020
Zafgen, Inc. (Nasdaq:ZFGN) today reported its fourth quarter and full year 2019 financial results.
-
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
12/18/2019
Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases
-
Zafgen Reports Third Quarter 2019 Financial Results
11/6/2019
Zafgen, Inc. (Nasdaq:ZFGN) today reported its third quarter 2019 financial results.
-
The lynchpin to biotech and pharmaceutical drug development in the United States is arguably the greater Boston area, which includes the white hot square mile of talent and intellectual collaboration found in Kendall Square.
-
Shares of Zafgen are down more than 22 percent in premarket trading after the company announced Monday that it was suspending plans to develop a treatment for Prader-Willi syndrome.
-
Shares of Boston-based Zafgen, Inc. plunged more than 32 percent in pre-market trading after the company announced the U.S. Food and Drug Administration has slapped a clinical hold on its plans to launch a clinical trial in the United States for an experimental diabetes medicine due to safety con...
-
Zafgen to Present Data from Multiple Nonclinical, IND-Enabling Studies of ZGN-1258 at the 2018 Foundation for Prader-Willi Research Family Conference
10/4/2018
Nonclinical data for ZGN-1258 reproduce efficacy seen in first generation candidate for PWS.
-
Navitor Appoints New CEO
8/3/2018
Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer. -
Shares of Denmark-based Saniona are up more than 14 percent on the Stockholm Exchange after the company announced it has been cleared to initiate the second part of a mid-stage trial to develop a treatment for adolescents with Prader-Willi Syndrome.
-
Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018
1/5/2018
The company will be returning to rare disorders with ZGN-1258.
-
Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
10/13/2017
-
Effective Immediately: Zafgen's Longtime CEO Becomes CSO, New Leader Named
10/10/2017
-
Zafgen Initiates Phase II Clinical Trial For ZGN-1061 In Patients With Type 2 Diabetes
9/13/2017
-
Zafgen Presents New Preclinical Data On ZGN-1061 At The 53rd Annual Meeting Of The European Association For The Study Of Diabetes
9/12/2017
-
Zafgen Reports Second Quarter 2017 Financial Results
8/9/2017
-
Zafgen To Host Conference Call To Discuss Second Quarter 2017 Financial Results
8/2/2017
-
Zafgen Reports First Quarter 2017 Financial Results
5/10/2017
-
Struggling Zafgen Catches A Break With Promising Early-Stage Obesity Data
5/5/2017
-
Zafgen To Host Conference Call To Discuss Fourth Quarter And Full Year 2016 Financial Results
3/3/2017